Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: December 2006
-
By Jason Derry — Reliance Life Sciences has announced that it will buy a controlling share of GeneMedix Plc. UK-based GeneMedix is a biopharmaceutical company whose core technology involves "protein development scale-up and manufacture" (see link). Reliance Life Sciences, based in India, "is developing business opportunities in the domains of medical biotechnology, plant…
-
By Christopher P. Singer — The USPTO presented a seminar today, December 20, 2006, that provided an overview of the new features now available on Private PAIR and announced the new Priority Document Exchange program (PDX). The presentation has been recorded and will be available within 48 hours at http://webex.client.ninesystems.com/pair122006. Private PAIR 7.0…
-
By Christopher P. Singer — In a December 19, 2006 press release, Pfizer Inc. announced that its Australian patent AU 601,981 covering atorvastatin (the active ingredient in Lipitor®) was upheld by the Australian Federal Court in Victoria. The ruling concluded Ranbaxy's 2005 lawsuit and imposes an injunction against Ranbaxy's generic product. The 601,981…
-
By Jason Derry — MedImmune, Inc. and Biowa, Inc. have announced a licensing and collaboration deal relating to development and commercialization of therapies for inflammatory diseases. In particular, the agreement relates to treatments that target interleukin-5 receptor. The companies have indicated that the initial focus will be on a monoclonal antibody, BIW-8405, which…
-
By Jason Derry — Alfacell Corp. and GENESIS Pharma S.A. have announced an exclusive licensing deal involving Alfacell's lead compound, ONCONASE®. The compound is in Phase IIIb clinical trials for the treatment of unresectable malignant mesothelioma. Under the agreement, GENESIS will receive the exclusive right to market and distribute ONCONASE® in Southeast Europe. Alfacell…
-
By Christopher P. Singer — The USPTO has asked Patent Docs to remind its readers that the Patent Office announcement regarding Private PAIR 7.0 and the EDX program, originally scheduled for December 19th, has been rescheduled for today (December 20th) at 1:00 pm Eastern time. The event can be accessed here.
-
By Christopher P. Singer — The U.S. Patent Office today announced that a limited group of Private PAIR users have been given the option of receiving electronic correspondence from the USPTO instead of paper mailings. The December 19, 2006 notice discusses an overview of the program and says that depending on its success,…
-
By Jason Derry — GlaxoSmithKline Plc. has announced a partnership with Genmab A/S relating to a particular antibody, HuMax-CD20, which is in late-stage clinical development for treating leukemia, lymphoma, and rheumatoid arthritis. Under the agreement, GSK will give Genmab an upfront payment of $103 million, and will purchase additional shares in the future,…
-
By Christopher P. Singer — Unfortunately, because of technical difficulties the U.S. Patent Office was unable to broadcast its presentation originally scheduled for 1:00 pm EST today, regarding the update to Private PAIR (Private PAIR 7.0). They hope to reschedule the event for sometime tomorrow. Earlier today, the PTO announced that this presentation…
-
By Mark Chael — AstraZeneca's European Patent No. EP 0 652 872 related to Nexium® was reviewed on December 19, 2006 by the Boards of Appeal at the European Patent Office. In 2003, this patent successfully survived an opposition filed by Ratiopharm GmbH of Germany. However, appeal no. T0401/04 was received on March…
Patent Docs 